Agreed, confirmation of the efficacy of MSC's is slowly building. There is:
Crohns disease (Alofisel which is approved in Europe/UK)
GVHD (approved in Japan and in the USA the ODAC voted 9:1 that it works for pediatric patients with steroid-refractory acute GVHD)
Chronic heart failure (MSB clinical trial found revascor provides a substantial and durable reduction in heart attacks, strokes and cardiac death)
As the list grows we should see more investors and money move into MSC/stem cell companies.
Cynata 6 month price target: $1.50 or just over a 200 million market cap based on new clinical trials starting and new partnerships.
Agreed, confirmation of the efficacy of MSC's is slowly...
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.72M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.0¢ | 20.0¢ | $4.156K | 20.74K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 54635 | 3 |
View Market Depth
| Last trade - 15.43pm 26/04/2024 (20 minute delay) ? |
| CYP (ASX) Chart |